ClearAlpha Technologies’s Vanda Pharmaceuticals VNDA Stock Holding History

ClearAlpha Technologies’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-60,000	Closed	-$275K	–	79
2025 Q1	$275K	Hold	60,000	–	–	0.17%	45
2024 Q4	$287K	Hold	60,000	–	–	0.2%	43
2024 Q3	$281K	Buy	60,000 +20,000	+50%	+$107K	0.08%	150
2024 Q2	$226K	Buy	+40,000	New	+$207K	0.07%	225

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

ClearAlpha Technologies's VNDA Position: Q2 2025 in Review

ClearAlpha Technologies sold out of Vanda Pharmaceuticals (VNDA) in Q2 2025, closing a stake of 60,000 shares — an estimated $275K sold.

ClearAlpha Technologies first reported a position in VNDA in Q2 2024 and held it in 4 quarters. The position peaked at $287K in Q4 2024. 139 funds tracked by Wall St. Rank hold VNDA as of Q2 2025.

ClearAlpha Technologies reported no remaining Vanda Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
ClearAlpha Technologies sold 60,000 Vanda Pharmaceuticals shares in Q2 2025, an estimated $275K.
ClearAlpha Technologies first reported a position in Vanda Pharmaceuticals in Q2 2024 and held it in 4 quarters.
ClearAlpha Technologies's Vanda Pharmaceuticals position peaked at $287K in Q4 2024.
139 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2025.

Based on ClearAlpha Technologies's 13F filing for Q2 2025, filed 14 Aug 2025.